Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

4.24
Delayed Data
As of 4:00pm ET
 +0.18 / +4.43%
Today’s Change
3.61
Today|||52-Week Range
11.15
-30.83%
Year-to-Date
3 Stocks on my Brexit Shopping List
10:06am / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close4.06
Today’s open4.15
Day’s range4.13 - 4.27
Volume642,075
Average volume (3 months)858,242
Market cap$284.0M
Dividend yield--
Data as of 4:00pm ET, 06/28/2016

Growth & Valuation

Earnings growth (last year)-1,033.33%
Earnings growth (this year)+117.41%
Earnings growth (next 5 years)+7.00%
Revenue growth (last year)-80.45%
P/E ratioNM
Price/Sales49.26
Price/Book3.14

Competitors

 Today’s
change
Today’s
% change
NLNKNewLink Genetics Cor...+0.88+8.84%
VSARVersartis Inc+0.35+3.56%
AKBAAkebia Therapeutics ...+0.43+5.94%
COLLCollegium Pharmaceut...+0.55+4.71%
Data as of 4:00pm ET, 06/28/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$0.13
Annual revenue (last year)$8.7M
Annual profit (last year)-$39.1M
Net profit margin-450.81%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark Robert Baker
Head-
Operations
Meryl J. Longval
Corporate headquarters
Tarrytown, New York

Forecasts

Partner Offers

Search for Jobs